Arcus Biosciences (RCUS) Stock Price & Analysis
RCUS$18.81+0.42 +2.28%
$2.37B
Market Cap
-4.72
P/E
16.46
Forward P/E
47
Score
Arcus Biosciences (RCUS) Stock Price & Analysis
RCUS price $18.81 +0.42 +2.28%
- Ticker
- RCUS
- Price
- $18.81
- Change
- +0.42 +2.28%
- Market cap ?
- $2.37B
- P/E ?
- -4.72
- Forward P/E ?
- 16.46
- Dividend yield ?
- 0.00%
- Beta ?
- 0.81
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 47
- Value
- 60
- Quality
- 30
- Growth
- 50
Stocklytics score rationale: value 60, quality 30, growth 50.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1413000 | 8353000 | 15000000 | 78000000 | 383000000 | 112000000 | 117000000 | 258000000 | 247000000 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1…
Insights · Dividends · Forecast · Financials · Learn